Chapitres éducatifs générés à partir d'entités OpenOnco YAML, ID source, cas synthétiques et métadonnées de révision. Ce n'est pas le contenu officiel de l'ESMO et ne accorde pas de crédit à CME.
DLBCL dossier d'examen de première ligne pour clinicien: scénarios synthétiques, sorties réelles, provenance de la source et retours exportables.
No chapters match the current filters.
Identify the histology, germline/tumor BRCA, HRD status, and platinum-response inputs needed before first-line ovarian-cancer maintenance selection.; Explain why platinum-based induction is the universal first-line backbone and how BRCA / HRD status route the
Identify the minimum diagnostic and biomarker inputs needed before first-line DLBCL treatment selection.; Explain how IPI risk, fitness, organ function, and biology influence R-CHOP versus Pola-R-CHP reasoning.; Recognize red flags that do not switch the regim
Identify the HER2-IHC/FISH workup, organ-function baseline, and ER/PR co-status needed before HER2+ metastatic first-line treatment selection.; Explain why docetaxel + trastuzumab + pertuzumab (THP) remains the standard first-line backbone in the OpenOnco mode
Prioritize ER/PR, HER2 (including HER2-low), germline BRCA, PIK3CA, ESR1, and AKT1 status before first-line HR+/HER2- metastatic breast cancer treatment selection.; Explain why an aromatase inhibitor plus a CDK4/6 inhibitor is the standard first-line backbone,
Identify the germline / somatic HRR panel, prior-line history, and disease-burden inputs needed before mCRPC first-line treatment selection.; Explain why ARPI continuation reasoning, BRCA/HRR routing to a PARP inhibitor, and Lu-177-PSMA / cabazitaxel options s
Prioritize MSI/MMR, RAS, BRAF, HER2, sidedness, and oligometastatic status before first-line mCRC treatment selection.; Explain why MSI-H/dMMR disease takes precedence over routine chemotherapy backbones.; Recognize when RAS wild-type left-sided disease and BR
Identify the BRAF V600 status, performance status, organ function, and disease-burden inputs needed before metastatic melanoma first-line treatment selection.; Explain why dual checkpoint inhibition (nivolumab + ipilimumab) is the standard immunotherapy backbo
Explain why metastatic NSCLC first-line reasoning starts with actionable driver testing before PD-L1-only decisions.; Distinguish EGFR, ALK, ROS1, MET exon 14, RET, BRAF V600E, and NTRK driver branches from driver-negative immunotherapy branches.; Recognize PD
Utiliser les risques cytogénétiques, les caractéristiques ISS/R-ISS, la fonction rénale, la fragilité et l'admissibilité à la transplantation comme axes de raisonnement MM de première ligne. Expliquer pourquoi les VRd et D-VRd apparaissent comme des pistes standard et alternatives de première gamme dans le modèle OpenOnco.
